Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC)

MLA

Anthony Doemer, et al. “Initial Reporting of NRG-LU001 (NCT02186847), Randomized Phase II Trial of Concurrent Chemoradiotherapy (CRT) +/- Metformin in Locally Advanced Non-Small Cell Lung Cancer (NSCLC).” Journal of Clinical Oncology, vol. 37, May 2019, p. 8502. EBSCOhost, https://doi.org/10.1200/jco.2019.37.15_suppl.8502.

APA

Anthony Doemer, Timothy Struve, Richard T. Lee, Chen Hu, Xuezhong Yang, Jeremy J. Erasmus, Rafael Santana-Davila, Bo Lu, Maria Werner-Wasik, Theodoros Tsakiridis, Jose G. Bazan, Jeffrey D. Bradley, James Coster, Gregory M.M. Videtic, Philip E. Schaner, Ronald C. McGarry, Benjamin Esparaz, Steven Eric McCormack, & Heath D. Skinner. (2019). Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 37, 8502. https://doi.org/10.1200/jco.2019.37.15_suppl.8502

Chicago

Anthony Doemer, Timothy Struve, Richard T. Lee, Chen Hu, Xuezhong Yang, Jeremy J. Erasmus, Rafael Santana-Davila, et al. 2019. “Initial Reporting of NRG-LU001 (NCT02186847), Randomized Phase II Trial of Concurrent Chemoradiotherapy (CRT) +/- Metformin in Locally Advanced Non-Small Cell Lung Cancer (NSCLC).” Journal of Clinical Oncology 37 (May): 8502. doi:10.1200/jco.2019.37.15_suppl.8502.